ReviewInternational urology and nephrology2026
Association between anti-PLA2R antibody status and clinical remission in primary membranous nephropathy: a systematic review and meta-analysis.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe anti-PLA2R antibody is a key biomarker for primary membranous nephropathy, and clarifying its association with clinical remission is crucial for optimizing prognostic assessment and clinical management. This study aimed to systematically evaluate the correlation between anti-PLA2R antibody status and clinical remission in patients with PMN.
methodsRelevant cohort studies were systematically searched and strictly screened from domestic and international databases in accordance with predefined inclusion and exclusion criteria. A total of 12 eligible cohort studies involving 1664 PMN patients were included in this meta-analysis.
resultsPooled quantitative analysis showed that anti-PLA2R antibody-positive patients had a significantly lower clinical remission rate compared with seronegative counterparts. The pooled RR was 0.75 (95% CI 0.61-0.92), P = 0.007, indicating a statistically significant difference between the two groups. The test for subgroup differences showed marginally different effect sizes across the three groups (X
conclusionAnti-PLA2R positivity predicts poorer 6-month remission in adult PMN, supporting KDIGO-guided early immunosuppression for high-risk patients. Heterogeneity mainly stems from inconsistent detection assays, and unified testing improves prognostic accuracy.
Indexed as
Identifiers
42507287What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.